Successful anti‐CD19 CAR T‐cell therapy in HIV‐infected patients with refractory high‐grade B‐cell lymphoma
JS Abramson, KE Irwin, MJ Frigault, J Dietrich… - Cancer, 2019 - Wiley Online Library
Cancer, 2019•Wiley Online Library
HIV‐positive patients have been excluded from clinical trials evaluating chimeric antigen
receptor (CAR) T‐cell therapies. Herein, the authors report on 2 patients with HIV/AIDS–
associated, chemotherapy‐refractory, aggressive B‐cell lymphomas who were treated
successfully with the anti‐CD19 CAR T‐cell product axicabtagene ciloleucel.
receptor (CAR) T‐cell therapies. Herein, the authors report on 2 patients with HIV/AIDS–
associated, chemotherapy‐refractory, aggressive B‐cell lymphomas who were treated
successfully with the anti‐CD19 CAR T‐cell product axicabtagene ciloleucel.
HIV‐positive patients have been excluded from clinical trials evaluating chimeric antigen receptor (CAR) T‐cell therapies. Herein, the authors report on 2 patients with HIV/AIDS–associated, chemotherapy‐refractory, aggressive B‐cell lymphomas who were treated successfully with the anti‐CD19 CAR T‐cell product axicabtagene ciloleucel.
Wiley Online Library